CellProthera announced a deal with Shonan Kamakura General Hospital (SKGH) to transfer technology to enable cell therapy manufacturing for clinical trials. The memorandum of understanding allows for GMP manufacturing of CD34+ endothelial progenitor cells (EPCs) for autologous therapy clinical trials. Takayuki Asahara of SKGH intends to adopt CellProthera’s StemXpand platform for clinical trials starting next…